The oncolytic virotherapy treatment platform for cancer: unique biological and biosafety points to consider

Cancer Gene Ther. 2002 Dec;9(12):1062-7. doi: 10.1038/sj.cgt.7700548.

Abstract

The field of replication-selective oncolytic viruses (virotherapy) has exploded over the last 10 years. As with many novel therapeutic approaches, initial overexuberance has been tempered by clinical trial results with first-generation agents. Although a number of significant hurdles to this approach have now been identified, novel solutions have been proposed and improvements are being made at a furious rate. This article seeks to initiate a discussion of these hurdles, approaches to overcome them, and unique safety and regulatory issues to consider.

Publication types

  • Review

MeSH terms

  • Clinical Trials as Topic
  • Genetic Therapy / methods*
  • Genetic Therapy / standards
  • Guidelines as Topic
  • Humans
  • Neoplasms / therapy*
  • Neoplasms / virology
  • Public Health
  • Risk Factors
  • Safety*
  • Viruses / genetics*
  • Viruses / pathogenicity